Introduction {#s1}
============

Background
----------

Pancreatic ductal adenocarcinoma (PDAC) is a lethal disease with a standardized incidence rate by age of 4.8 and a standardized mortality rate of 4.4 per 100,000 persons worldwide ([@B1]). During the last decades, the prognosis of most common cancer types has dramatically improved, but this is not the case of PDAC. Indeed, despite recent improvements, PDAC 5-years survival rate is only \~8% ([@B2]). This is because the majority of PDAC patients show unspecific symptoms, and the diagnosis is usually made only at an advanced stage of the disease ([@B3]). In addition, no population screening program is available ([@B4]). More than 450,000 patients are diagnosed with PDAC worldwide every year, with a significant burden for the health and socioeconomic systems.

The diagnosis of PDAC in most cases is completely unforeseen by the patient, who faces the disease suddenly, often already at an advanced stage, and without a progressive approach to it. The clinical interview in which the diagnosis and the first information regarding treatment options and prognosis are communicated, therefore, is a key moment.

Doctor--patient communication is considered "time of care," as stated by the Italian law n.219/2017 ([@B5]). In light of that, correct communication is an integral part of the care itself and lays the foundations for the construction of the therapeutic alliance between the treating physician and the patient, which is essential to guarantee compliance with the proposed treatments. There are, however, few studies conducted on doctor--patient communication in cancer patients ([@B6]) and none specifically on PDAC patients.

Many recent studies claim that a good level of patient engagement is an essential condition to build a solid therapeutic alliance ([@B7], [@B8]); in this regard, objective measurement scales of the patient engagement level have been developed and have been demonstrated to be useful tools to quantify the patient\'s involvement within the care process ([@B9], [@B10]). Among them is the Patient Health Engagement Scale (PHE-S®), a recently validated assessment scale of simple and non-invasive use, which requires only the administration of a questionnaire ([@B11]).

Hypothesis
----------

The hypothesis to be tested is that clarity of communication between the treating physician and the patient at the time of diagnosis, and the patient\'s level of understanding of the information received, influences a patient\'s engagement and compliance with the care process.

Aims
----

This study aims to (1) collect quantitative data about the level of PDAC patients engagement and their rate of understanding of the received information and (2) investigate the association between engagement and rate of understanding and of these two variables with the level of compliance.

Methods and Analysis {#s2}
====================

Study Design
------------

This will be a monocentric cohort study (observational, cross-sectional) on PDAC patients.

Patients
--------

Consecutive outpatients visited by three expert physicians at the Gastroenterology, Pancreatic Surgery and Oncology Clinics of the Pancreas Translational and Clinical Research Center, IRCCS San Raffaele, Milan (Italy) will be considered includable if they meet the following conditions: adult patients (≥18 years)of Italian mother tonguehave a histological diagnosis of PDAC obtained during the 4 weeks prior to the visitthe visit is their first visit, after completion of diagnostic procedures and is the occasion in which diagnosis and/or treatment strategies are communicatedgive full, written, informed consent.

The following exclusion criteria will be applied: PDAC recurrence after previous diagnosis and treatmentpoor performance status \[Eastern Cooperative Oncology Group (ECOG) ≥ 3\].

Variables
---------

The following variables will be recorded in a dedicated Case Report Form (CRF): age, sex, region of origin, educational level of the patient, habits such as smoking and alcohol intake as previously reported ([@B12]), date of the histological diagnosis of pancreatic adenocarcinoma, its stage, and the proposed treatment plan.

The level of patient engagement will be evaluated through the PHE-s® (see [Appendix 1](#SM1){ref-type="supplementary-material"}).

The rate of understanding of the information received from the patient by the doctor will be determined during a semistructured interview (see [Appendix 2](#SM1){ref-type="supplementary-material"}) by comparing the number of information conveyed by the doctor with the number of information received/correctly understood by the patient.

The compliance with treatments will be defined as the rate of treatments received compared to what was proposed and planned by the treating physicians and was considered possible by the medical team in light of patient\'s conditions and side effects.

Study Period
------------

The enrolment is planned to start from June 2020 and will last until the planned number of enrolled patients has been met.

Outcomes
--------

The association between the level of engagement, as evaluated by the PHE-s®, and the patient\'s rate of understanding during the diagnostic interview, will be assessed to evaluate whether the degree of clarity of the information provided by the doctor influences the level of patient engagement.

The association between the level of patient engagement is calculated with the PHE-s® and patient\'s estimated rate of understanding according to the interview and the adherence to proposed treatments (compliance).

Description of the Intervention (Schedule of Visits)
----------------------------------------------------

The study requires (i) the completion of the scheduled outpatients visit with a gastroenterologist, surgeon, or oncologist with strong expertise in PDAC, (ii) the filling of the PHE-S® questionnaire by the patient to investigate the level of engagement, and (iii) the completion of a semistructured interview to assess the rate of understanding of the information received from the doctor.

In more detail: The treating physician will inform the patient about the study before starting the outpatient visit and communicating information on PDAC diagnosis and planned treatments. The treating physician will also ask permission to the patient regarding the presence during the visit of an external observer (a Ph.D. student in philosophy of language and communication), who will take notes regarding the information provided and will record the audio of the visit if the patient gives further (optional) consent.After the visit, the external observer will ask the patient further written informed consent to use the data collected during the interview and to complete the study. Informed consent forms are presented at this stage rather than at a preliminary stage to avoid anticipating the diagnosis of PDAC, which the patient might not have yet received from the doctor.The patient will be asked to fill in the PHE-s® questionnaire, which takes \~10 min to be completed. PHE-s® is a standardized and validated tool to measure patients\' psychological readiness to engage in patients with different medical disorders.The external observer will conduct a semistructured interview of \~30 min to ask the patient questions concerning the clarity of the communication he had received from the doctor and the type of language used, to record the rate of understanding of the information. This phase will ideally take place following the PHE-s® questionnaire, but the patient will be free to postpone it to another moment or day given the possible difficulties for the patient to face an interview immediately following the communication of the diagnosis. The interview will be conducted by an expert observer in the field of language and communication (a Ph.D. student in philosophy of language and communication). The object of the interview is the language used by the treating physician and its clarity for the patient.

All patients will then be treated and followed up normally in the context of the multidisciplinary team of the Pancreas Center that also include the aid of "navigator" and "research" nurses.

The Medication of the Study
---------------------------

The study is observational, so a preplanned treatment is not considered.

Statistical Analysis
--------------------

Categorical variables will be compared using Fisher or chi-square tests and continuous variables using *t* test or Mann--Whitney tests, as appropriate. Subgroups with different levels of engagement will be compared for variables such as sex, age, education, geographic area, stage of disease, type of proposed treatment, and other available data. The PHE-s® questionnaire provides continuous data. The possible correlation of the level of engagement with the clarity of the received information that will be considered as a categorical variable divided in quartiles and with the compliance with treatments will be tested by a Pearson test. Two different univariate and multivariate logistic regression analyses will be run considering patient engagement and compliance as outcome variables and patients\' and disease features and the clarity of communication as explanatory variables.

The "enter" method will be employed including all variables that had resulted to be significant at the univariate analysis. Tests of statistical significance and confidence intervals will be two-sided; a *p* \< 0.05 will be considered to be statistically significant. A dedicated software (Medcalc 12.1, Belgium) will be employed.

Power Size Calculation
----------------------

There have been no previous studies on the association between the patient\'s understanding rate and the level of engagement and the consequent level of compliance in patients with PDAC. This is, therefore, a pilot study, and power size cannot be calculated. Considering that at S. Raffaele Hospital, some 500 new PDAC patients are seen per year, with the established inclusion criteria, it is considered plausible that 45--60 patients will be enrolled in 3 months.

Discussion {#s3}
==========

Active engagement of the patient to the therapeutic program has been shown to be an important factor not only to obtain improved compliance but also to improve the outcomes ([@B13], [@B14]).

Data on the communication between physicians and patients with PDAC are scanty, and patients\' engagement has not been systematically evaluated in this context ([@B15]).

We hypothesize that the clarity of communication between the treating physician and the patient and the degree of comprehension by the patient, especially during the first phases of the cure, are associated with the level of engagement and consequently with the compliance of patients with PDAC.

If the present pilot study will support this initial hypothesis, further action to improve the clarity of the clinical communication will be promoted.
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